Inhibition of drug transporter breast cancer resistance protein has no effect on the pharmacokinetics of major active metabolites of ozanimod

被引：0
|
作者：
Zhang, P. [1 ]
Ghosh, A. [1 ]
Thomas, M. [1 ]
Wang, X. [1 ]
Palmisano, M. [1 ]
Tran, J. [1 ]
机构：
[1] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0343
引用
收藏
页码：285 / 285
页数：1
相关论文
共 50 条
  • [1] WARFARIN IS A SUBSTRATE OF BREAST CANCER RESISTANCE PROTEIN, AN EFFLUX DRUG TRANSPORTER
    Yang, Meng-Syuan
    Yu, Chung-Ping
    Lin, Shiuan-Pey
    Chao, Pei-Dawn Lee
    Hou, Yu-Chi
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S105 - S106
  • [2] Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Pharmacokinetics of Sunitinib in Rats
    Kunimatsu, Sachiko
    Mizuno, Tomoyuki
    Fukudo, Masahide
    Katsura, Toshiya
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (08) : 1592 - 1597
  • [3] Breast cancer resistance protein: Molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics
    Sugimoto, Y
    Tsukahara, S
    Ishikawa, E
    Mitsuhashi, J
    CANCER SCIENCE, 2005, 96 (08) : 457 - 465
  • [4] P-Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects
    Bhardwaj, Rajinder
    Collins, Julie L.
    Stringfellow, Joseph
    Madonia, Jennifer
    Anderson, Matt S.
    Finley, Jeri-anne
    Stock, David A.
    Coric, Vladimir
    Croop, Robert
    Bertz, Richard
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (07): : 889 - 897
  • [5] Upregulation of breast cancer resistance protein and major vault protein in drug resistant epilepsy
    Dixit, Aparna Banerjee
    Sharma, Devina
    Srivastava, Arpna
    Banerjee, Jyotirmoy
    Tripathi, Manjari
    Prakash, Deepak
    Chandra, P. Sarat
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2017, 47 : 9 - 12
  • [6] Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients
    Yamagata, Tetsuo
    Kusuhara, Hiroyuki
    Morishita, Mariko
    Takayama, Kozo
    Benameur, Hassan
    Sugiyama, Yuichi
    DRUG METABOLISM AND DISPOSITION, 2007, 35 (07) : 1142 - 1148
  • [7] Compartmental modelling of the pharmacokinetics of a breast cancer resistance protein
    Grandjean, Thomas R. B.
    Chappell, Mike J.
    Yates, James T. W.
    Jones, Kevin
    Wood, Gemma
    Coleman, Tanya
    COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2011, 104 (02) : 81 - 92
  • [8] A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2)
    Matsson, Par
    Englund, Gunilla
    Ahlin, Gustav
    Bergstrom, Christel A. S.
    Norinder, Ulf
    Artursson, Per
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 323 (01): : 19 - 30
  • [9] Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
    de Wolf, Cornelia
    Jansen, Robert
    Yamaguchi, Hiroaki
    de Haas, Marcel
    de Wetering, Koen van
    Wijnholds, Jan
    Beijnen, Jos
    Borst, Piet
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (09) : 3092 - 3102
  • [10] Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects
    Tran, Jonathan Q.
    Zhang, Peijin
    Walker, Susan
    Ghosh, Atalanta
    Syto, Mary
    Wang, Xiaomin
    Harris, Sarah
    Palmisano, Maria
    ADVANCES IN THERAPY, 2020, 37 (12) : 4944 - 4958
12345